INFORMATION
Infliximab is a recombinant protein that has the potential to induce humoral immune responses and lead to anti-drug antibody formation; a major cause of loss of response.
These Anti-drug antibodies bind and neutralise the TNFα inhibitors accelerating their clearance and reduces the efficacy of the drugs. Monitoring the efficacy of TNFα inhibitors may help clinicians schedule a successful individualised treatment strategy for their patients.
Total Anti-Infliximab Antibody ELISA
TOTAL anti-drug antibody ELISAs enable the detection of anti-drug antibodies in the presence of circulating drug, and so are often called “Drug Tolerant” assays. The benefit of drug-tolerant assays is being able to detect lower titres of Anti-drug antibodies which could become clinically significant in certain circumstances.
Total anti-drug Antibody assays offer a greater sensitivity, unmasking the drug-bound portion of anti-drug antibodies in circulation. TOTAL anti-drug antibody analysis may be advantageous when using combination therapy such as immunosuppressants due to this increased sensitivity.
IDKmonitor® Infliximab total-Anti-drug Antibody ELISA is a quantitative assay that involves a pre-analytical step to dissociate the anti-drug antibodies of interest from the therapeutic Infliximab. The separated therapeutic Infliximab is replaced by a biotinylated version of the drug, forming a the new complex which can be captured and quantified on the streptavidin coated microplate.
FEATURES
-
Drug tolerant assay for Infliximab anti-drug antibodies
-
Detects Total anti-infliximab antibodies in Serum and Plasma
-
Preanalytical step to dissociate therapeutic drug from target anti-drug antibody
-
1 calibrator, 2 controls
-
Capacity for 45 samples in duplicate
-
Automatable on ELISA automates (e.g. Dynex D2)
BENEFITS
-
Supports the investigation of primary non response and loss of response to Infliximab
-
Drug tolerant assay detects total anti-infliximab antibodies (those free- and bound to- infliximab)
-
Helps predict long term outcome of disease in patients with sub-therapeutic infliximab levels
-
Identifies patients with low-titre anti-infliximab antibodies (e.g. in the case of concomitant immunosuppressant)
-
UK publications and evidence base
-
Widely available via reference laboratories in UK and Ireland
-
Applicable to Gastroenterology, Rheumatology
